Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Mucociliary ClearanceEnrolling Location: Multiple care centres across the US

    Phase 1Bstudy of inhaled AZD5634 in adults with CF , protocol number NCT02950805

    This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the inhaled drug AZD5634 in adults with CF.

    • Age:

      18 - 60 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      4

    • Length of Participation:

      4 months

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: Multiple care centres across the US

    RESULT: Study of liprotamase non-porcine enzymes , protocol number NCT03051490

    This randomized, parallel-assignment study is taking place at multiple care centres across the US. It will look at the effectiveness of liprotamase, a non-pig derived pancreatic enzyme replacement therapy (PERT), as compared to a pig-derived PERT.

    • Age:

      7 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      17

    • Length of Participation:

      30 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 1/2 Study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis. , protocol number NCT03140527

    This study is taking place at multiple care centres across the US. It will look at the safety and tolerability of the drug PTI-801

    • Age:

      18 years and over

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      8

    • Length of Participation:

      30

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis. , protocol number SAVARA SAV005

    This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

    • Age:

      6 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      30-100%

    • Number of Visits:

      8

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple US sites

    Vertex Lumacaftor (VX-809) and Ivacaftor in children with CF aged 6 to 11 years and have two copies of the delF508 CFTR mutation. , protocol number VX13-809-011b

    This was an open-label study designed to look at the safety of lumacaftor in combination with ivacaftor (Orkambi). This study was for younger children with CF who have two copies of the F508del CFTR mutation.

    • Age:

      6-11 years

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      11

    • Length of Participation:

      27 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 2 stduy of VX-152 combination drug in people with cystic fibrosis. , protocol number Vertex VX-152-102

    This study is taking place at multiple care centres accross the US. It will look at the safety and tolerability of the drug VX-152 in combination with both ivacaftor and tezacaftor (VX-661).

    • Age:

      18 years and older

    • Mutation(s):

      homozygous or hetrozygous F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      10

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Does vibration training improve muscle power, bone strength and physical function in children and adolescents with cystic fibrosis. , protocol number ACTRN12609000520235

    A study to examine th effects of home based whole body vibration training on increasing muscle in children 6-18 years.

    • Age:

      6 - 18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      > 25%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Australia

    An open-label, rollover study to evaluate the long term safety and efficacy of VX-770 in subjects with Cystic Fibrosis , protocol number VX08-770-105 PERSIST ACTRN12610000491066

    Study 105 (VX08-770-105) is an open-label, VX-770 treatment extension of Study VX08-770-102 (Study 102) and Study VX08-770-103 (Study 103). This rollover study evaluates the long-term safety and efficacy of treatment with the experimental drug, VX-770, for a duration of up to 96 weeks. Male and female subjects 6 years and older with cystic fibrosis who have completed Study 102 or 103 without major protocol violations are eligible to enrol. This project is an international, multi-centre trial, with subjects from 70 sites worldwide including Australia, Europe and North America. [Study 102: NCT00909532] [Study 103: NCT00909727]

    • Age:

      > 6 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      up to 96 weeks

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Effect of nebulised saline on lung function and quality of life in patients with CF. , protocol number ACTRN12610000754044

    This study will compare 1. compare different concentrations of hypertonic saline delivered via a new fast nebuliser 2. determine whether hypertonic saline is tolerable when delivered via a new fast nebuliser 3. Compare the response to hypertonic saline of patients with badly affected lungs to those patients with mild-moderately affected lungs.

    • Age:

      > 6 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherNot yet recruiting Location: NSW - Australia

    Randomised trial of positive expiratory pressure (PEP) to improve deposition in participants with CF. , protocol number ACTRN12612000017820

    Study aims to determine whether the addition of PEP improves the uniformity of deposition of inhaled aerosol in CF patients. Deposition scan following radioaerosol inhalation with and without PEP will be analysed and compared to data from healthy participants.

    • Age:

      >18 years

    • Mutation(s):

      Not Specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 41-50 (of 142)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|